Business Context and Reporting Period
This Form 8-K is a current report filed by Galectin Therapeutics Inc. on July 26, 2021. The filing serves as a Regulation FD disclosure regarding a video posted on the company's corporate website featuring Dr. Ben Carson, Senior Scientific Advisor, alongside company executives and directors discussing the company's progress.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of non-financial corporate communications and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing solely announces the availability of a summary video regarding company progress.
Guidance, Outlook, and Risks
- Management Commentary: The video contains summary information on company progress but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Forward-Looking Statements: The content includes forward-looking statements identified by terms such as "anticipate," "believe," "expect," and "plan."
- Risks and Uncertainties: Actual results may differ materially from forward-looking statements due to risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2020.
- Limitations: The company undertakes no obligation to update forward-looking statements except as required by law.
Key Facts for Investor Verification
- Verify the content of the video available at the company's website (https://galectintherapeutics.com/video-library/).
- Review the "Risk Factors" section of the Form 10-K for the year ended December 31, 2020, to understand the uncertainties affecting forward-looking statements.
- Note that the information in this 8-K is furnished and not incorporated by reference into other filings.
- Confirm that no financial data is presented in this specific filing.